717 related articles for article (PubMed ID: 32800831)
1. Erythropoietin maintains VE-cadherin expression and barrier function in experimental diabetic retinopathy via inhibiting VEGF/VEGFR2/Src signaling pathway.
Liu D; Xu H; Zhang C; Xie H; Yang Q; Li W; Tian H; Lu L; Xu JY; Xu G; Liu K; Sun X; Xu GT; Zhang J
Life Sci; 2020 Oct; 259():118273. PubMed ID: 32800831
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier.
Kim SR; Suh W
Arch Pharm Res; 2017 Feb; 40(2):197-203. PubMed ID: 27988882
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy.
Xie H; Zhang C; Liu D; Yang Q; Tang L; Wang T; Tian H; Lu L; Xu JY; Gao F; Wang J; Jin C; Li W; Xu G; Xu GT; Zhang J
Diabetologia; 2021 Jan; 64(1):211-225. PubMed ID: 33104828
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin protects outer blood-retinal barrier in experimental diabetic retinopathy by up-regulating ZO-1 and occludin.
Zhang C; Xie H; Yang Q; Yang Y; Li W; Tian H; Lu L; Wang F; Xu JY; Gao F; Wang J; Jin C; Xu G; Xu GT; Zhang J
Clin Exp Ophthalmol; 2019 Dec; 47(9):1182-1197. PubMed ID: 31483932
[TBL] [Abstract][Full Text] [Related]
5. Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats.
Huang J; Li X; Li M; Li S; Xiao W; Chen X; Cai M; Wu Q; Luo D; Tang S; Luo Y
Diabetes Obes Metab; 2012 Jul; 14(7):644-53. PubMed ID: 22340191
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.
Ting KK; Zhao Y; Shen W; Coleman P; Yam M; Chan-Ling T; Li J; Moller T; Gillies M; Vadas MA; Gamble JR
Diabetologia; 2019 Feb; 62(2):322-334. PubMed ID: 30443753
[TBL] [Abstract][Full Text] [Related]
7. Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R.
Cai S; Yang Q; Hou M; Han Q; Zhang H; Wang J; Qi C; Bo Q; Ru Y; Yang W; Gu Z; Wei R; Cao Y; Li X; Zhang Y
Cell Physiol Biochem; 2018; 45(2):505-522. PubMed ID: 29402864
[TBL] [Abstract][Full Text] [Related]
8. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling.
Heinolainen K; Karaman S; D'Amico G; Tammela T; Sormunen R; Eklund L; Alitalo K; Zarkada G
Circ Res; 2017 Apr; 120(9):1414-1425. PubMed ID: 28298294
[TBL] [Abstract][Full Text] [Related]
9. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy.
Rangasamy S; Srinivasan R; Maestas J; McGuire PG; Das A
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3784-91. PubMed ID: 21310918
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes.
Zhang J; Wu Y; Jin Y; Ji F; Sinclair SH; Luo Y; Xu G; Lu L; Dai W; Yanoff M; Li W; Xu GT
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):732-42. PubMed ID: 18235022
[TBL] [Abstract][Full Text] [Related]
11. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.
Sun Z; Li X; Massena S; Kutschera S; Padhan N; Gualandi L; Sundvold-Gjerstad V; Gustafsson K; Choy WW; Zang G; Quach M; Jansson L; Phillipson M; Abid MR; Spurkland A; Claesson-Welsh L
J Exp Med; 2012 Jul; 209(7):1363-77. PubMed ID: 22689825
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats.
Mitsuhashi J; Morikawa S; Shimizu K; Ezaki T; Yasuda Y; Hori S
Exp Eye Res; 2013 Jan; 106():64-73. PubMed ID: 23178551
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.
Lee CS; Kim YG; Cho HJ; Park J; Jeong H; Lee SE; Lee SP; Kang HJ; Kim HS
Sci Rep; 2016 Jul; 6():29393. PubMed ID: 27381080
[TBL] [Abstract][Full Text] [Related]
14. LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis.
Liu P; Jia SB; Shi JM; Li WJ; Tang LS; Zhu XH; Tong P
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988072
[No Abstract] [Full Text] [Related]
15. The cKit Inhibitor, Masitinib, Prevents Diabetes-Induced Retinal Vascular Leakage.
Kim SR; Im JE; Jeong JH; Kim JY; Kim JT; Woo SJ; Sung JH; Park SG; Suh W
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1201-6. PubMed ID: 26978025
[TBL] [Abstract][Full Text] [Related]
16. Silencing Nogo-B improves the integrity of blood-retinal barrier in diabetic retinopathy via regulating Src, PI3K/Akt and ERK pathways.
Yang Q; Zhang C; Xie H; Tang L; Liu D; Qiu Q; Luo D; Liu K; Xu JY; Tian H; Lu L; Xu GT; Zhang J
Biochem Biophys Res Commun; 2021 Dec; 581():96-102. PubMed ID: 34662809
[TBL] [Abstract][Full Text] [Related]
17. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin.
Smith RO; Ninchoji T; Gordon E; André H; Dejana E; Vestweber D; Kvanta A; Claesson-Welsh L
Elife; 2020 Apr; 9():. PubMed ID: 32312382
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-A
Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
[TBL] [Abstract][Full Text] [Related]
19. LECT2 Ameliorates Blood-Retinal Barrier Impairment Secondary to Diabetes Via Activation of the Tie2/Akt/mTOR Signaling Pathway.
Qin YJ; Xiao K; Zhong Z; Zhao Y; Yu T; Sun XF
Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):7. PubMed ID: 35262733
[TBL] [Abstract][Full Text] [Related]
20. Src-induced tyrosine phosphorylation of VE-cadherin is not sufficient to decrease barrier function of endothelial monolayers.
Adam AP; Sharenko AL; Pumiglia K; Vincent PA
J Biol Chem; 2010 Mar; 285(10):7045-55. PubMed ID: 20048167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
